Study S002056

A Multicenter, Randomized, Open-label, Parallel-controlled Phase III Study Comparing the Efficacy and Safety of HRS9531 Injection Versus Semaglutide Injection in Subjects With Obesity

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07285902
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 572
Start: 2025-12-25
Primary completion: 2027-03
Lead sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
Conditions: Obesity
Interventions: DRUG:HRS9531 injection; DRUG:Semaglutide Injection
Results posted: FALSE
Individual participant data sharing: UNDECIDED

Registered primary outcomes

Percentage change from baseline in body weight after 52 weeks of treatment [52 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.